Overview

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Status:
Withdrawn
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Cerulean Pharma Inc.
NewLink Genetics Corporation
Treatments:
Camptothecin